Lilly Alzheimer’s asset targeting tau protein fails in phase 2
by
Contributor since / Followers
Contributor since / Followers
3 months ago
selvanegra/iStock via Getty Images
- LY3372689, an Eli Lilly (NYSE:LLY) Alzheimer’s candidate targeting the enzyme O-GlcNAcase as a way to reduce the formation of tau protein in the brain, missed its primary endpoint in a phase 2 trial.
- The drugmaker made the announcement earlier Thursday during its Q2 financial results call. Two doses were tested in the study, and neither led to a reduction in an Alzheimer’s severity scale over time.
- “While this negative outcome was disappointing, we remain committed to tap as a high conviction target in Alzheimer’s disease and plan to continue studying tau biology,” Chief Scientific Officer Dan Skovronsky said.
- Lilly’s recently approved Alzheimer’s med Kisunla (donanemab) targets amyloid beta plaque, a peptide found in the brain of many Alzheimer’s patients.
- The pharma still has several other Alzheimer’s candidates in the pipeline, including remternetug in phase 3 and mevidalen in phase 2 for mild to moderate Alzheimer’s dementia.